COMP <GO>
GMAB vs TEVA // EV/EBITDA & P/E VALUATION
Genmab A/S ADS (NASDAQ) VS. Teva Pharmaceutical Industries Limited (NYSE) • 15-METRIC TALLY: GMAB 9
— TEVA 2
▲ EV/EBITDA & P/E VALUATION LEADER: TEVA
LAST: $57.06 (+1.01%) • MKT CAP: $35.25B
valuation
21.0x
LAST: $42.09 (+1.50%) • MKT CAP: $48.32B
valuation
20.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GMAB VS. TEVA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GMAB | TEVA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 51.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 9.40% | +0.50 | GMAB | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.0x | 20.8x | +0.20 | TEVA | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | 1.81% | +0.40 | GMAB | /fcf-yield <GO> |
| Operating Margin | 13.90% | 12.50% | +1.40 | GMAB | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 8.20% | +2.70 | GMAB | /net-margins <GO> |
| Revenue Growth (YoY) | 22.00% | 4.30% | +17.70 | GMAB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.74 | 1.02 | +2.72 | GMAB | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 85.2 | 58.6 | +26.60 | GMAB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.09 | 1.00 | +0.09 | GMAB | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.6x | 31.9x | -4.30 | GMAB | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $35.25B | $48.32B | -$13.07B | TEVA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GMAB REV | TEVA REV | GMAB GROSS % | TEVA GROSS % | GMAB FCF | TEVA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $17.26B | — | 51.8% | — | $872.4M |
| FY 2024 | — | $16.54B | — | 48.7% | — | $502.5M |
| FY 2023 | — | $15.85B | — | — | — | $654.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GMAB // BETA 1.09
TEVA // BETA 1.00